Literature DB >> 25984812

Osteoarthritis increases the risk of dementia: a nationwide cohort study in Taiwan.

Shih-Wei Huang1, Wei-Te Wang2, Lin-Chung Chou3, Chun-De Liao3, Tsan-Hon Liou4, Hui-Wen Lin5.   

Abstract

Osteoarthritis (OA) and dementia are prevalent causes of disability in geriatric patients. To date, information on the temporal correlation between these progressive diseases and the risk of dementia in patients with OA is limited. This retrospective population-based 4-year cohort study investigated the risk of dementia in patients with OA. We performed a case-control matched analysis by using the Taiwan Longitudinal Health Insurance Database 2005. Patients were selected on the basis of International Classification of Diseases, Ninth Revision, Clinical Modification codes for OA between January 1, 2004 and December 31, 2007. The prevalence and the adjusted hazard ratio (HR) of dementia in patients with and without OA were estimated. The OA cohort comprised 35,149 patients and the non-OA cohort (comparison cohort) comprised 70,298 patients (1:2). The incidence of dementia was 21.7 per 10,000 person-years in the OA cohort and 14.7 per 10,000 person-years in the non-OA cohort. The HR for dementia during the follow-up period was 1.33 (95% confidence interval [CI], 1.17-1.50, P < 0.001) for patients with OA. The adjusted HR for dementia was 1.25 (95% CI, 1.10-1.43, P < 0.001) for patients with OA. The results of this study indicated that OA is an independent risk factor for dementia.

Entities:  

Mesh:

Year:  2015        PMID: 25984812      PMCID: PMC4434986          DOI: 10.1038/srep10145

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Osteoarthritis (OA) of the knee is one of the leading causes of disability among noninstitutionalized elderly adults1. Consequences of severe knee OA, including loss of mobility and limited daily activities, affect individuals and society economically. The World Health Organization (WHO) Global Burden of Disease Study, conducted in 21 epidemiological regions worldwide, reported a 26.6% increase in the burden of knee OA from 1990 to 20102. Although nonsteroidal antiinflammatory therapy, exercise, and control of body weight remain the primary treatment options, there is no effective treatment for severe knee and hip OA, and total joint replacement is typically the final and only effective solution for relieving pain and disability. Dementia, an age-related disease characterised by a gradual decline in mental abilities that affects reasoning, memory, and other cognitive functions, is one of the major causes of mortality in patients with knee and hip OA34. The incidence of dementia is 10% in people aged older than 65 years and approximately 20% in people aged older than 80 years. The prevalence of dementia in people older than 65 years was estimated to be 7.29% in Western Europe, 5.65% in South Asia, 8.50% in Latin America, and 4.98% in East Asia5. The prevalence of neurodegenerative disorders is increasing because of changes in the population demographics. As of 2010, 35.6 million people worldwide were diagnosed with dementia, and the numbers were estimated to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 20505. Health care costs can impose a substantial economic burden on patients with dementia6. Moreover, dementia causes a decline in cognitive and social functioning that interferes with independent living, affecting the individual and increasing the burden on family members and caregivers7. Therefore, preventing dementia in geriatric patients is crucial. The correlation between OA and dementia has not been investigated thoroughly. An animal study reported that OA can accelerate the progression of and exacerbate Alzheimer’s disease (AD) by causing peripheral inflammation, triggering neuroinflammation, and inducing AD pathogenesis8. A previous study reported that primary total knee replacement can improve not only the knee function but also the mental health of patients with OA and mental disability. We hypothesized that OA can be an accelerating factor in the development of dementia. However, information regarding the occurrence of dementia after the onset of OA is limited. No large-scale nationwide population study has investigated OA and the risk of dementia. Therefore, we conducted a retrospective population-based case-controlled cohort study to investigate the risk of dementia among patients with OA.

Methods

Study design and study population

Data source

This retrospective population-based cohort study was conducted using case-control matched analysis. The patient data were obtained from the Taiwan Longitudinal Health Insurance Database 2005 (LHID2005). In March 1995, the National Health Insurance programme was established in Taiwan, and currently has over 25 million enrolees, covering more than 99% of the population of Taiwan. The LHID2005 comprises claims data for 1,000,000 beneficiaries randomly sampled from the Registry for Beneficiaries of the National Health Insurance Research Database (NHIRD), which contains 25.68 million claims files. The claims files contain information on ambulatory care; inpatient care; pharmacy use; date of service; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes; and claimed medical expenses. The National Health Research Institutes (NHRI) manages the claims data and provides scrambled random identification numbers for insured patients to protect patient privacy. Because the NHIRD comprises deidentified secondary data that were analysed anonymously, the need for informed consent in this study was waived.

Study patients

Between January 1, 2004 and December 31, 2007, patients whose ambulatory care claims contained ICD-9-CM code 715 (OA) were identified. For an accurate diagnosis of OA, patients who received at least 5 consistent diagnoses according to the ICD-9-CM in outpatient clinics or a primary diagnosis of OA during hospitalisation within 1 year were selected. Initially, 35,901 OA patients were enrolled in this study. However, 450 patients were excluded because of missing data, and 302 OA patients with a previous sustained diagnosis of dementia (ICD-9-CM code 290) were also excluded. The OA cohort comprised 35,149 patients with OA, and the non-OA cohort comprised 70,298 patients without OA who were matched with the patients with OA in a 1:2 ratio according to age and sex. Each patient was monitored for as many as 4 years, from the patient’s entry date until the patient received 2 consecutive diagnoses of dementia (ICD-9-CM codes 290, 294, and 331) in outpatient clinics or 1 primary diagnosis during hospitalisation, or until the end of 2011. The database consists of deidentified secondary data, and the data were analyzed anonymously; therefore, the need for informed consent was waived.

Baseline comorbidities

Baseline variables, namely age, diabetes mellitus (DM; ICD-9-CM codes 250 and 251), hypertension (ICD-9-CM codes 401−405), hyperlipidaemia (ICD-9-CM codes 272.0−272.4), autoimmune disease (rheumatoid arthritis [RA], ICD-9-CM code 714.0; systemic lupus erythematosus [SLE], ICD-9-CM code 710.0), cerebral vascular accident (CVA; ICD-9-CM codes 430−438), chronic obstructive pulmonary disease (COPD; ICD-9-CM code 496), and Parkinson’s disease (ICD-9-CM code 332), were obtained for all patients.

Statistical analysis

First, we calculated the dementia hazard function for as many as 4 years by using the Cox model to examine the differences in the risk of dementia between the 2 OA and non-OA cohorts, after adjusting for patient physical characteristics, namely age and sex; comorbidities, namely DM, hyperlipidaemia, RA, CVA, COPD, and Parkinson’s disease; and the external factor of urbanisation level. To adjust for the hospital cluster random effect, we proposed a frailty model for modelling corrections among the dementia diagnoses of hospital clusters, incorporating a random component for the hazard function.

Let the hazard function for the ith patient in the kth hospital cluster be

, where h0(t) is the baseline hazard function, x is the vector of the fixed-effect covariance (including OA, age, sex, autoimmune disease, DM, hypertension, hyperlipidaemia, CVA, COPD, and Parkinson’s disease), β is the regression coefficient, andτ is the random effect for the hospital cluster. Let τ ~ iidN(0,Δ). The penalised partial log likelihood is , where l(β) is the partial likelihood function for the Cox model. Thus, the marginal log likelihood of this shared frailty model is Using a Laplace approximation, we computed the optimal linear unbiased predictors of β,τ and Δ by maximising the penalised partial log likelihood91011. All data analyses were performed using the SAS statistical package (Version 9.1.3; SAS Institute, Cary, NC, USA). A P value of <0.05 was considered statistically significant.

Results

The OA cohort comprised 35,149 patients with OA, and the non-OA cohort comprised 70,298 patients without OA. Women constituted 63.2% in both cohorts, and the prevalence of comorbidities was higher in the OA cohort than in the non-OA cohort (Table 1). The incidence of dementia was 21.7 per 10,000 person-years in the OA cohort, whereas it was 14.7 per 10,000 person-years in the non-OA cohort. In patients with OA, the crude hazard ratio (HR) for developing dementia was 1.33 (P < 0.001), and the adjusted HR was 1.25 (P < 0.001; Table 2). Figure 1 shows the Kaplan–Meier hazard curves for dementia in the OA and non-OA cohorts over a 4-year follow-up period. The log-rank test analysis in Fig 1 revealed that patients in the OA cohort had higher hazard rates (HR = 1.24, P < 0.001) than did patients in the non-OA cohort. According to the Cox regression analysis, the HR for dementia during the follow-up period was 1.32 (95% confidence interval [CI], 1.17−1.49) for the OA cohort compared with the non-OA cohort. After adjustment for patient age and sex, DM, hyperlipidaemia, hypertension, coronary heart disease, COPD, stroke, and Parkinson’s disease in hospital or clinics, the HR for dementia during the 4-year follow-up period was 1.22 (95% CI, 1.07−1.38) for patients in the OA cohort (Table 3).
Table 1

Demographic characteristics and comorbidities for patients in the OA and non-OA cohorts from 2004 to 2007.

Baseline variableOA cohort n = 35,149
Non-OA cohort n = 70, 298
P value
 No ( %)No ( %) 
Characteristics
Sex
Female2221663.24443263.2 
Male1293336.82586636.8 
Age (years)
18–305031.410061.4 
31–4010242.920482.9 
41–50359910.2719810.2 
51–60716220.41432420.4 
61–701043029.72086029.7 
>701243135.42486235.4 
Autoimmune disease (RA, SLE)    <0.001
Yes32059.123673.4 
No3194490.96793196.6 
DM    <0.001
Yes999728.41634723.3 
No2515271.65395176.7 
Hypertension    <0.001
Yes2147561.13473449.4 
No1367438.93556450.6 
Hyperlipidaemia    <0.001
Yes1341738.21761425.1 
No2173261.85268474.9 
Coronary heart disease    <0.001
Yes1141032.51513521.5 
No2373967.55516378.5 
COPD    <0.001
Yes1335938.01872826.6 
No2179062.05157073.4 
Stroke    <0.001
Yes715620.41154916.4 
No2799379.65874983.6 
Parkinson’s disease    <0.001
Yes12833.717452.5 
No3386696.36855397.5 

RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease

Table 2

Crude and adjusted hazard ratios (HR) for dementia between patients in the OA and non-OA cohorts during the 4-year follow-up period, starting from the index date of ambulatory care visit (n = 105,447).

Presence of dementiaNon-OA patientsOA patients
4-year follow-up period
Yes/Total (%)650/70298 (0.92)421/35149 (1.19)
Person-years442020193732
Incidence per 10,000 person-years14.721.7
Crude HR (95% CI)1.001.33* (1.17–1.50)
Adjusteda HR (95% CI)1.001.25* (1.10–1.43)

aAdjustments were made for age, sex, autoimmune disease, DM, hypertension, hyperlipidaemia, coronary heart disease, stroke, COPD, and Parkinson’s disease.*indicates P < 0.001

Figure 1

Kaplan–Meier hazard curve for dementia in osteoarthritis (OA) patients and the controls over a 4-year follow-up period.

Table 3

Adjusted HRs for dementia in the OA and non-OA cohorts determined using the frailty model.

Presence of dementia during the 4-year follow-up period
 Crude HR (95% CI)Adjusted HR (95% CI)P value for adjusted HR
OA1.32 (1.17–1.49)1.21 (1.07–1.38)0.002
Age (year)1.09 (1.08–1.10)1.08 (1.07–1.09)<0.001
Sex (M)0.90 (0.79–1.02)0.73 (0.65–0.83)<0.001
Autoimmune disease1.22 (0.95–1.55)1.14(0.90–1.46)0.299
DM1.73 (1.53–1.96)1.25 (1.10–1.42)<0.001
Hypertension2.57 (2.24–2.95)1.06 (0.92–1.23)0.381
Hyperlipidaemia0.98 (0.86–1.12)0.92 (0.80–1.05)0.218
Coronary heart disease1.85 (1.63–2.09)0.94 (0.82–1.07)0.342
Parkinson’s disease8.44 (7.26–9.82)2.98 (2.54–3.49)<0.001
COPD2.15 (1.91–2.42)1.27 (1.12–1.44)<0.001
Stroke6.58 (5.83–7.43)3.14 (2.75–3.58)<0.001

To adjust for the hospital cluster random effect, we proposed the frailty model.

Discussion

Our study revealed that OA patients are at a high risk for dementia. This longitudinal cohort study is the first large-scale population-based study to investigate the risk of dementia in patients with OA. A community cohort study of geriatric patients with chronic, painful hip or knee OA reported that uncontrolled symptoms can cause functional disability and fatigue, which in turn lead to a depressed mood and ADL dependence12. In addition, patients with OA exhibit a high coprevalence of other chronic diseases. Among patients with OA, 90% have at least one additional chronic disease, of which cardiovascular diseases are the most common. Weight-bearing activities such as walking can exacerbate the pain and reduce the activity level of patients with OA13. A lack of physical activity may result in poor fitness and a higher risk of cardiovascular disease1415. Nuesch et al. studied the causes of mortality in patients with OA and reported high mortality rates for all disease-specific causes of death, particularly for deaths associated with cardiovascular diseases and dementia3. Previous studies have reported the preventive effects of physical activity and exercise on dementia later in later16171819. We suggest that improving physical activity after joint replacement is crucial in preventing dementia, particularly in geriatric patients with OA. Pain relief and restoration of ambulation function can enable patients to achieve higher levels of physical activity. A prospective cohort study revealed a strong correlation between total daily activity and a lower risk of dementia20. In addition, obesity is a key risk factor for OA, as indicated by the high prevalence of hip and knee OA in overweight patients21. Furthermore, a recent population-based study indicated that high midlife leisure and physical activity levels protect against dementia and AD, particularly in overweight people22. Studies have suggested that physical activity reduces cardiovascular risk by controlling blood pressure and exerting positive effects on brain structures21232425. Conversely, discontinuing daily activities because of OA can expose patients with OA to a higher risk of dementia. OA is a slow degenerative disease, and the pathogenesis of OA includes loss of articular cartilage with subchondral bone remodelling. Proinflammatory cytokines induce inflammation, which is one of the pathological mechanisms of OA development26. Interleukin-1 (IL-1) and tumour necrosis factor (TNF alpha) are the key proinflammatory cytokines that induce cartilage catabolism in patients with OA262728. Similarly, peripheral inflammation may be associated with an increased risk of dementia. In addition, previous studies have revealed associations between the serum levels of proinflammatory cytokines such as IL-1b, IL-6, and TNF alpha, which all increase the risk of dementia and AD.910111213141516171819202122232425262728293031. An animal model study revealed that OA with peripheral inflammation triggers neuroinflammation and subsequently induces AD pathogenesis8. Therefore, we hypothesised that inflammation caused by OA is one of the possible mechanisms of dementia development. Another possible mechanism through which patients with OA develop dementia is related to the influence of the depression symptoms of OA patients. A meta-analysis reported that patients with a history of depression were highly likely to be diagnosed with dementia later in life32. The prevalence of depression is 18% in patients with arthritis aged older than 45 years in the United States33. Another article stated that approximately 19% of patients with OA experience moderate-to-severe depression, reporting that chronic pain and impairment of daily activities caused by OA play a crucial role in depression34. A previous study revealed that knee joint replacement can improve both mental health and knee function, particularly in patients with OA and a poor preoperative mental health status35. Therefore, we infer that a poor mental status caused by OA is among the risk factors contributing to dementia development. This study had several limitations that must be addressed. First, the diagnosis of dementia and medical comorbidities was determined using ICD-9-CM codes from the NHRID; however, no information on the accuracy of these codes is available. To reduce the bias caused by the incorrect use of codes, we included only patients who received 5 consecutive diagnoses of OA in outpatient clinics or a primary diagnosis of OA during hospitalisation. Second, information on daily physical activity, individual behaviour, and psychological status is not recorded in the NHIRD. These factors are crucial in the development of dementia; however, quantifying these parameters in such a large database is challenging. Finally, the NHIRD does not include data on body weight or the severity and duration of OA. We controlled for age as one of the confounding factors in both cohorts, potentially eliminating this bias because OA is a degenerative disease.

Conclusion

Patients with OA are at a higher risk for dementia than are those without OA. Impaired daily physical activity, OA-induced inflammatory processes, and depression are possible mechanisms of dementia development. Multidisciplinary interventions that involve controlling pain and symptoms of depression, preventing the decline of physical function, and encouraging participation in leisure activities can be used for OA patients to prevent the development dementia. In the future, studies can focus on the prevention of dementia by controlling the progression of OA symptoms.

Author Contributions

S.W.H. conceptualised and designed the study and drafted the article; S.W.H. and H.W.L. analysed and interpreted the data; S.W.H. and C.D.L. critically revised the article for important intellectual content; T.H.L. and H.W.L. provided final approval of the article; L.C.C. provided study materials and patients; H.W.L. offered statistical expertise; and W.T.W. provided administrative, technical, and logistical support.

Additional Information

How to cite this article: Huang, S.-W. et al. Osteoarthritis Increases the Risk of Dementia: A Nationwide Cohort Study in Taiwan. Sci. Rep. 5, 10145; doi: 10.1038/srep10145 (2015).
  32 in total

1.  Estimation of multivariate frailty models using penalized partial likelihood.

Authors:  S Ripatti; J Palmgren
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

Review 2.  Physical activity and risk of cognitive decline: a meta-analysis of prospective studies.

Authors:  F Sofi; D Valecchi; D Bacci; R Abbate; G F Gensini; A Casini; C Macchi
Journal:  J Intern Med       Date:  2010-09-10       Impact factor: 8.989

3.  A prospective examination of the relationship between physical activity and dementia risk in later life.

Authors:  Mary Elizabeth Bowen
Journal:  Am J Health Promot       Date:  2012 Jul-Aug

Review 4.  Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging.

Authors:  J Eric Ahlskog; Yonas E Geda; Neill R Graff-Radford; Ronald C Petersen
Journal:  Mayo Clin Proc       Date:  2011-09       Impact factor: 7.616

5.  How "bad" does the pain have to be? A qualitative study examining adherence to pain medication in older adults with osteoarthritis.

Authors:  Joanna E M Sale; Monique Gignac; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2006-04-15

6.  Primary total knee replacement in patients with mental disability improves their mental health and knee function: a prospective study.

Authors:  N D Clement; D MacDonald; R Burnett
Journal:  Bone Joint J       Date:  2013-03       Impact factor: 5.082

Review 7.  Cytokines in osteoarthritis: mediators or markers of joint destruction?

Authors:  C I Westacott; M Sharif
Journal:  Semin Arthritis Rheum       Date:  1996-02       Impact factor: 5.532

8.  Predictors of depression in a sample of 1,021 primary care patients with osteoarthritis.

Authors:  Thomas Rosemann; Matthias Backenstrass; Katharina Joest; Andrea Rosemann; Joachim Szecsenyi; Gunter Laux
Journal:  Arthritis Rheum       Date:  2007-04-15

9.  Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort.

Authors:  Anna-Maija Tolppanen; Tiia Ngandu; Ingemar Kåreholt; Tiina Laatikainen; Minna Rusanen; Hilkka Soininen; Miia Kivipelto
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

10.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Theo Vos; Abraham D Flaxman; Mohsen Naghavi; Rafael Lozano; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Richard Gosselin; Rebecca Grainger; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jixiang Ma; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

View more
  24 in total

1.  Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis.

Authors:  Weidong Zhang; Guang Sun; Dawn Aitken; Sergei Likhodii; Ming Liu; Glynn Martin; Andrew Furey; Edward Randell; Proton Rahman; Graeme Jones; Guangju Zhai
Journal:  Rheumatology (Oxford)       Date:  2016-05-09       Impact factor: 7.580

2.  Association of osteoarthritis and pain with Alzheimer's Diseases and Related Dementias among older adults in the United States.

Authors:  M Ikram; K Innes; U Sambamoorthi
Journal:  Osteoarthritis Cartilage       Date:  2019-06-12       Impact factor: 6.576

3.  Arthritis and cognitive impairment in older adults.

Authors:  Nancy A Baker; Kamil E Barbour; Charles G Helmick; Matthew Zack; Soham Al Snih
Journal:  Rheumatol Int       Date:  2017-03-23       Impact factor: 2.631

4.  Cause-Specific Mortality Trends Following Total Hip and Knee Arthroplasty.

Authors:  Clement J Michet; Cathy D Schleck; Dirk R Larson; Hilal Maradit Kremers; Daniel J Berry; David G Lewallen
Journal:  J Arthroplasty       Date:  2016-10-20       Impact factor: 4.757

5.  The Potential Contribution of Chronic Pain and Common Chronic Pain Conditions to Subsequent Cognitive Decline, New Onset Cognitive Impairment, and Incident Dementia: A Systematic Review and Conceptual Model for Future Research.

Authors:  Kim E Innes; Usha Sambamoorthi
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  The Association of Osteoarthritis and Related Pain Burden to Incident Alzheimer's Disease and Related Dementias: A Retrospective Cohort Study of U.S. Medicare Beneficiaries.

Authors:  Kim E Innes; Usha Sambamoorthi
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

7.  Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B.

Authors:  Kuo-Tung Tang; Wei-Ting Hung; Yi-Hsing Chen; Ching-Heng Lin; Der-Yuan Chen
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

8.  Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis C.

Authors:  Kuo-Tung Tang; Yi-Hsing Chen; Ching-Heng Lin; Der-Yuan Chen
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

9.  Specific premature epigenetic aging of cartilage in osteoarthritis.

Authors:  Laura Vidal-Bralo; Yolanda Lopez-Golan; Antonio Mera-Varela; Ignacio Rego-Perez; Steve Horvath; Yuhua Zhang; Álvaro Del Real; Guangju Zhai; Francisco J Blanco; Jose A Riancho; Juan J Gomez-Reino; Antonio Gonzalez
Journal:  Aging (Albany NY)       Date:  2016-09-28       Impact factor: 5.682

10.  Pain is not associated with cognitive decline in older adults: A four-year longitudinal study.

Authors:  Nicola Veronese; Ai Koyanagi; Marco Solmi; Trevor Thompson; Stefania Maggi; Patricia Schofield; Christoph Mueller; Catharine R Gale; Cyrus Cooper; Brendon Stubbs
Journal:  Maturitas       Date:  2018-07-03       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.